While there is currently no available data on the use of anti-TNF-α drugs for treating HPS3-related IBD, these biologic drugs or even surgical interventions must be considered in our case to prevent severe complications if the clinical response to the current treatment goes worse and the disease progresses faster. The gene discussed is HPS3; the disease is inflammatory bowel disease.